Pfizer to shut Chennai, Aurangabad units; 1,700 workers likely to be affected
text_fields
Mumbai: U.S.-based pharma major Pfizer on Wednesday said it plans to shut down its manufacturing units in Chennai and Aurangabad in the current fiscal due to very significant long-term loss of product demand. The closure is expected to impact nearly 1,700 workers.
The company’s Irungattukottai unit in Tamil Nadu currently employs approximately 1,000 workers and Maharashtra’s Aurangabad site employs approximately 700. The exact timing of the exit of these sites is yet to be determined, the firm said.
The recommendation to exit both the sites are the result of significant loss of product demand, making manufacturing at these sites unviable, the company said.
“Pfizer has conducted a thorough evaluation of the IKKT (Irungattukottai) and Aurangabad sites and concluded that due to the very significant long-term loss of product demand, manufacturing at these sites is not viable.
As a result, both sites will immediately cease manufacturing with the intention to exit as soon as possible in 2019. The exact timing of the exit is to be determined,” a Pfizer spokesperson said. Both plants are purely export-oriented sites and do not supply products for Pfizer’s India commercial operations, it said.
